About scpharmaceuticals - SCPH
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
SCPH At a Glance
scPharmaceuticals, Inc.
25 Burlington Mall Road
Burlington, Massachusetts 01830
| Phone | 1-617-517-0730 | Revenue | 13.59M | |
| Industry | Pharmaceuticals: Major | Net Income | -54,810,000.00 | |
| Sector | Health Technology | Employees | 136 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
SCPH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 17.765 |
| Price to Book Ratio | 6.059 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.756 |
| Enterprise Value to Sales | 15.136 |
| Total Debt to Enterprise Value | 0.196 |
SCPH Efficiency
| Revenue/Employee | 99,948.529 |
| Income Per Employee | -403,014.706 |
| Receivables Turnover | 3.028 |
| Total Asset Turnover | 0.124 |
SCPH Liquidity
| Current Ratio | 7.076 |
| Quick Ratio | 6.403 |
| Cash Ratio | 5.787 |
SCPH Profitability
| Gross Margin | 71.964 |
| Operating Margin | -407.533 |
| Pretax Margin | -403.222 |
| Net Margin | -403.222 |
| Return on Assets | -50.129 |
| Return on Equity | -99.972 |
| Return on Total Capital | -70.734 |
| Return on Invested Capital | -58.763 |
SCPH Capital Structure
| Total Debt to Total Equity | 108.198 |
| Total Debt to Total Capital | 51.969 |
| Total Debt to Total Assets | 42.622 |
| Long-Term Debt to Equity | 107.725 |
| Long-Term Debt to Total Capital | 51.742 |